131 related articles for article (PubMed ID: 7536196)
1. Intermittent interferon and polychemotherapy in metastatic melanoma.
Vuoristo MS; Gröhn P; Kellokumpu-Lehtinen P; Kumpulainen E; Turunen M; Korpela M; Joensuu H; Tiusanen K; Nevantaus A
J Cancer Res Clin Oncol; 1995; 121(3):175-80. PubMed ID: 7536196
[TBL] [Abstract][Full Text] [Related]
2. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T
J Clin Oncol; 1992 Dec; 10(12):1919-26. PubMed ID: 1280673
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
[TBL] [Abstract][Full Text] [Related]
4. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
Kivelä T; Suciu S; Hansson J; Kruit WH; Vuoristo MS; Kloke O; Gore M; Hahka-Kemppinen M; Parvinen LM; Kumpulainen E; Humblet Y; Pyrhönen S
Eur J Cancer; 2003 May; 39(8):1115-20. PubMed ID: 12736111
[TBL] [Abstract][Full Text] [Related]
5. Complete responses and survival after polychemotherapy plus interferon-alpha for patients with metastatic melanoma.
Vuoristo MS
Melanoma Res; 1996 Aug; 6(4):331-6. PubMed ID: 8873054
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
Punt CJ; van Herpen CM; Jansen RL; Vreugdenhil G; Muller EW; de Mulder PH
Br J Cancer; 1997; 76(2):266-9. PubMed ID: 9231931
[TBL] [Abstract][Full Text] [Related]
7. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.
Nathan FE; Berd D; Sato T; Shield JA; Shields CL; De Potter P; Mastrangelo MJ
J Exp Clin Cancer Res; 1997 Jun; 16(2):201-8. PubMed ID: 9261748
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
Vuoristo MS; Hahka-Kemppinen M; Parvinen LM; Pyrhönen S; Seppä H; Korpela M; Kellokumpu-Lehtinen P
Melanoma Res; 2005 Aug; 15(4):291-6. PubMed ID: 16034308
[TBL] [Abstract][Full Text] [Related]
9. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma.
York RM; Foltz AT
Cancer; 1988 Jun; 61(11):2183-6. PubMed ID: 2452681
[TBL] [Abstract][Full Text] [Related]
10. Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha.
Mattila K; Raanta P; Lahtela V; Pyrhönen S; Koskivuo I; Vihinen P
Anticancer Res; 2018 Nov; 38(11):6393-6397. PubMed ID: 30396963
[TBL] [Abstract][Full Text] [Related]
11. Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon-alpha for metastatic melanoma.
Reinhold U; Bruske T; Kreysel HW
Eur J Cancer; 1996 Jan; 32A(1):180. PubMed ID: 8695233
[No Abstract] [Full Text] [Related]
12. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B
Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789
[TBL] [Abstract][Full Text] [Related]
14. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.
Hernberg M; Muhonen T; Turunen JP; Hahka-Kemppinen M; Pyrhönen S
J Clin Oncol; 1996 May; 14(5):1690-6. PubMed ID: 8622089
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
16. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-alpha.
Vuoristo M; Gröhn P; Kumpulainen E; Korpela M
Eur J Cancer; 1994; 30A(3):420. PubMed ID: 7515632
[No Abstract] [Full Text] [Related]
18. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
